These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23881910)

  • 1. Interactions between alcohol and the HIV entry inhibitor Maraviroc.
    Gruber VA; Rainey PM; Lum PJ; Beatty GW; Aweeka FT; McCance-Katz EF
    J Int Assoc Provid AIDS Care; 2013; 12(6):375-7. PubMed ID: 23881910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-HIV agents. Maraviroc--absorption and drug-interaction issues.
    TreatmentUpdate; 2007; 19(3):5. PubMed ID: 17571441
    [No Abstract]   [Full Text] [Related]  

  • 3. Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.
    Taiwo B; Acosta EP; Ryscavage P; Berzins B; Lu D; Lalezari J; Castro J; Adeyemi O; Kuritzkes DR; Eron JJ; Tsibris A; Swindells S
    J Acquir Immune Defic Syndr; 2013 Oct; 64(2):167-73. PubMed ID: 23797691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir.
    Andrews E; Glue P; Fang J; Crownover P; Tressler R; Damle B
    Br J Clin Pharmacol; 2010 Jan; 69(1):51-7. PubMed ID: 20078612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral administration of the CCR5 inhibitor, maraviroc, blocks HIV ex vivo infection of Langerhans cells within the epithelium.
    Matsuzawa T; Kawamura T; Ogawa Y; Takahashi M; Aoki R; Moriishi K; Koyanagi Y; Gatanaga H; Blauvelt A; Shimada S
    J Invest Dermatol; 2013 Dec; 133(12):2803-2805. PubMed ID: 23648547
    [No Abstract]   [Full Text] [Related]  

  • 6. A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.
    Pozniak AL; Boffito M; Russell D; Ridgway CE; Muirhead GJ
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):54-9. PubMed ID: 18333866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.
    Forbes CJ; Lowry D; Geer L; Veazey RS; Shattock RJ; Klasse PJ; Mitchnick M; Goldman L; Doyle LA; Muldoon BC; Woolfson AD; Moore JP; Malcolm RK
    J Control Release; 2011 Dec; 156(2):161-9. PubMed ID: 21864598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.
    Lu Y; Fuchs EJ; Hendrix CW; Bumpus NN
    Drug Metab Dispos; 2014 Nov; 42(11):1796-802. PubMed ID: 25117426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical pharmacokinetic of maraviroc].
    Peytavin G
    Med Mal Infect; 2008 Mar; 38 Suppl 1():S12-6. PubMed ID: 18455057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques.
    Malcolm RK; Forbes CJ; Geer L; Veazey RS; Goldman L; Klasse PJ; Moore JP
    J Antimicrob Chemother; 2013 Mar; 68(3):678-83. PubMed ID: 23111849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy.
    Waters L; Jackson A; Else L; Rockwood N; Newell S; Back D; Nelson M; Gazzard B; Boffito M
    Antivir Ther; 2015; 20(2):157-63. PubMed ID: 24963558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.
    Mora-Peris B; Croucher A; Else LJ; Vera JH; Khoo S; Scullard G; Back D; Winston A
    J Antimicrob Chemother; 2013 Jun; 68(6):1348-53. PubMed ID: 23364475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.
    Fox J; Tiraboschi JM; Herrera C; Else L; Egan D; Dickinson L; Jackson A; Olejniczak N; Back D; Khoo S; Shattock R; Boffito M
    J Acquir Immune Defic Syndr; 2016 Nov; 73(3):252-257. PubMed ID: 27727157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial.
    Chen BA; Panther L; Marzinke MA; Hendrix CW; Hoesley CJ; van der Straten A; Husnik MJ; Soto-Torres L; Nel A; Johnson S; Richardson-Harman N; Rabe LK; Dezzutti CS
    J Acquir Immune Defic Syndr; 2015 Nov; 70(3):242-9. PubMed ID: 26034880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods.
    Gonzalez-Serna A; McGovern RA; Harrigan PR; Vidal F; Poon AF; Ferrando-Martinez S; Abad MA; Genebat M; Leal M; Ruiz-Mateos E
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1202-7. PubMed ID: 22143533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects.
    Vourvahis M; Langdon G; Labadie RR; Layton G; Ndongo MN; Banerjee S; Davis J
    Antimicrob Agents Chemother; 2012 Feb; 56(2):887-92. PubMed ID: 22123705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetics, interactions and mechanism of action of maraviroc].
    Soriano V; Poveda E
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():12-6. PubMed ID: 19133216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment.
    Abel S; Davis JD; Ridgway CE; Hamlin JC; Vourvahis M
    Antivir Ther; 2009; 14(6):831-7. PubMed ID: 19812445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When and how to use maraviroc in HIV-infected patients.
    Soriano V; Perno CF; Kaiser R; Calvez V; Gatell JM; di Perri G; Pillay D; Rockstroh J; Geretti AM
    AIDS; 2009 Nov; 23(18):2377-85. PubMed ID: 19834318
    [No Abstract]   [Full Text] [Related]  

  • 20. A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients.
    D'Avolio A; Simiele M; Baietto L; Siccardi M; Sciandra M; Patanella S; Bonora S; Di Perri G
    Ther Drug Monit; 2010 Feb; 32(1):86-92. PubMed ID: 20040898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.